Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 635

1.

An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors including DNA repair proteins and Nrf2.

Cardnell RJ, Behrens C, Diao L, Fan YH, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA.

Clin Cancer Res. 2015 Apr 15. pii: clincanres.3286.2014. [Epub ahead of print]

PMID:
25878335
2.

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.

Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R; Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN.

Genome Med. 2015 Feb 2;7(1):21. doi: 10.1186/s13073-015-0135-5. eCollection 2015.

3.

A decision support framework for genomically informed investigational cancer therapy.

Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv098. doi: 10.1093/jnci/djv098. Print 2015 Jul.

PMID:
25863335
4.

Characterization of the role rab25 in energy metabolism and cancer using extracellular flux analysis and material balance.

Mitra S, Molina J, Mills GB, Dennison JB.

Methods Mol Biol. 2015;1298:195-205. doi: 10.1007/978-1-4939-2569-8_17.

PMID:
25800844
5.

Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai ZA.

Cancer Cell. 2015 Mar 9;27(3):354-69. doi: 10.1016/j.ccell.2015.02.006.

PMID:
25759021
6.

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF.

Cancer Res. 2015 Mar 15;75(6):1091-101. doi: 10.1158/0008-5472.CAN-14-1854. Epub 2015 Mar 3.

PMID:
25736685
7.

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L.

J Clin Invest. 2015 Apr 1;125(4):1459-70. doi: 10.1172/JCI78954. Epub 2015 Feb 23.

PMID:
25705882
8.

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F.

J Natl Cancer Inst. 2015 Feb 16;107(3). pii: dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar.

PMID:
25688104
9.

Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.

Tuna M, Ju Z, Smid M, Amos CI, Mills GB.

Mol Cancer. 2015 Feb 3;14(1):29. doi: 10.1186/s12943-015-0289-1.

10.

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT.

Oncogene. 2015 Feb 2. doi: 10.1038/onc.2014.469. [Epub ahead of print]

PMID:
25639871
11.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK.

Clin Chem. 2015 Mar;61(3):544-53. doi: 10.1373/clinchem.2014.231100. Epub 2015 Jan 27.

PMID:
25626406
12.

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM.

Oncotarget. 2015 Feb 20;6(5):2604-14.

13.

Shrewd AKT regulation to survive.

Dawood M, Mills GB, Ding Z.

Oncoscience. 2014 Mar 17;1(2):113-4. eCollection 2014. No abstract available.

14.

RET fusion as a novel driver of medullary thyroid carcinoma.

Grubbs EG, Ng PK, Bui J, Busaidy NL, Chen K, Lee JE, Lu X, Lu H, Meric-Bernstam F, Mills GB, Palmer G, Perrier ND, Scott KL, Shaw KR, Waguespack SG, Williams MD, Yelensky R, Cote GJ.

J Clin Endocrinol Metab. 2015 Mar;100(3):788-93. doi: 10.1210/jc.2014-4153. Epub 2014 Dec 29.

PMID:
25546157
15.

α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration.

Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS.

Cancer Res. 2015 Jan 1;75(1):203-15. doi: 10.1158/0008-5472.CAN-13-3563. Epub 2014 Dec 12.

PMID:
25503560
16.

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB.

Cancer Cell. 2014 Dec 8;26(6):863-79. doi: 10.1016/j.ccell.2014.10.010.

PMID:
25490449
17.

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.

Berg A, Hoivik EA, Mjøs S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Øyan AM, Kalland KH, Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C, Salvesen HB.

Oncotarget. 2015 Jan 20;6(2):1327-39.

18.

In silico prediction of physical protein interactions and characterization of interactome orphans.

Kotlyar M, Pastrello C, Pivetta F, Lo Sardo A, Cumbaa C, Li H, Naranian T, Niu Y, Ding Z, Vafaee F, Broackes-Carter F, Petschnigg J, Mills GB, Jurisicova A, Stagljar I, Maestro R, Jurisica I.

Nat Methods. 2015 Jan;12(1):79-84. doi: 10.1038/nmeth.3178. Epub 2014 Nov 17.

PMID:
25402006
19.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

20.

Development of a robust classifier for quality control of reverse-phase protein arrays.

Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, Davies MA, Akbani R, Weinstein JN, Mills GB, Coombes KR.

Bioinformatics. 2015 Mar 15;31(6):912-8. doi: 10.1093/bioinformatics/btu736. Epub 2014 Nov 6.

PMID:
25380958
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk